Table 1.
Variable | Controls (n=55) | HIV + (n=106) | P |
---|---|---|---|
Mean (SD) Age, y | 12.3 (3.8) | 14.8 (4.3) | <0.001 |
Percent female | 43 | 56 | 0.14 |
Race, % | 0.04 | ||
Black | 78 | 62 | |
Hispanic | 18 | 24 | |
White/other | 4 | 15 | |
Mean (SD) Weight z-score | 0.55 (1.2) | 0.26 (1.3) | 0.17 |
Mean (SD) Height z-score | 0.19 (.98) | −0.46 (1.2) | <0.001 |
Mean (SD) BMI z-score | 0.51 (1.2) | 0.51 (1.1) | 0.99 |
Mean (SD) Body fat, % | … | 24 (13) | |
Mean (SD) Trunk fat, % | … | 24 (14) | |
Mean (SD) Waist circumference, cm | … | 76 (15) | |
Mean (SD) Hip circumference, cm | … | 86 (15) | |
Mean (SD) Waist:hip ratio | … | 0.89 (0.07) | |
Disease Characteristics | |||
CDC Stage, % | |||
Stage A | … | 22 | |
Stage B | … | 34 | |
Stage C | … | 39 | |
Stage N | … | 6 | |
Mean (SD) CD4, % | … | 27 (13) | |
Median [IQR] Viral load | … | 882 [50, 11500] | |
% Receiving HAART | … | 86 | |
Mean (SD) duration of HAART, y | … | 6.0 (3.1) | |
% Receiving Protease Inhibitors | … | 80 | |
Mean (SD) duration of PI therapy, y | … | 5.0 (3.3) | |
% Receiving NRTI | … | 90 | |
Mean (SD) duration of NRTI, y | … | 9.2 (4.6) | |
% Receiving NNRTI | … | 11 | |
Mean (SD) duration of NNRTI therapy, y | … | 2.3 (2.6) |
IQR = interquartile range; HAART = highly active antiretroviral therapy; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor